



ASX ANNOUNCEMENT

Lumos Diagnostics Quarterly Activity Statement and Cash Flow Report

Key Highlights from the Fourth Quarter of Financial Year 2026

- **FebriDx® CLIA waiver milestone payments** – CLIA waiver key milestone payments of US\$5.0 million from PHASE Scientific and US\$0.5 million from BARDA received
- **FY26 total revenue of US\$13.2 million**, up 6% over the pcp, with FebriDx revenue up 875%
- **U.S. commercialisation of FebriDx® progressing well** with 170+ healthcare locations across 24 states actively ordering and using FebriDx®
- **FebriDx® Paediatric study milestone payment** – completed Milestone #7 following enrolment of 250 patients to-date in the BARDA-funded paediatric study, triggering a milestone payment of US\$0.7 million
- **Hologic fFN project continues** with Phases 2 and 3 work, including the additional scope of works in progress, which have extended the project estimated completion date out to June 2028
- **Operating cash inflow** for Q4 was US\$2.7 million with higher receipts from customers
- **Cash balance of US\$15.4 million** at 30 June 2026

All amounts are in USD, the Company's reporting currency, unless otherwise stated.

MELBOURNE, Australia (27 July 2026) – Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid point-of-care diagnostic technologies, is pleased to release its Quarterly Activity Statement and Appendix 4C Quarterly Cash Flow Report for the fourth quarter of FY26 (Q4 FY26 / the three months ended 30 June 2026).

Operational Update

Revenue Summary:

US\$000	Quarter 4			Full Year (12 months)		
	FY26	FY25	Mv't	FY26	FY25	Mv't
Products	162	317	-49%	4,282	1,823	+135%
Services	2,088	2,308	-10%	8,910	10,577	-16%
Total	2,250	2,625	-14%	13,192	12,400	+6%

Full Year FY26 Review

Unaudited revenue for FY26 was up 6% on pcp to US\$13.2 million, with the Products business reporting a 135% increase to US\$4.3 million, and the Services business a 16% decline to revenue of US\$8.9 million.

The Products business delivered strong growth, driven by FebriDx® which reported revenue of US\$3.9 million, an 875% increase on the pcp of US\$0.4 million. This growth was primarily attributable to sales orders from Lumos' exclusive U.S. distributor, PHASE Scientific (PHASE).

Sales from the third-party supplied CorDx Flu A/B/COVID combo test, introduced as a replacement for Lumos' proprietary ViraDx® test, following its loss of price competitiveness, of \$0.2 million were unable to match the sales levels achieved by ViraDx in the pcp. As a result, sales in this product line declined by US\$1.1 million compared to the pcp.

The decline in Services business revenue compared with the pcp was primarily attributable to the extension of the Hologic fFN project timeline. This extension reduced the revenue recognised from the amortization of the Hologic IP licence fee, resulting in revenue for this line item declining from US\$4.6 million in FY25 to US\$1.4 million in FY26. Excluding this reduction in IP licence fee revenue, revenue from projects grew by US\$1.5 million to US\$7.5 million in FY26, an increase of 24% over the pcp, reflecting continued progress across customer projects and increased contract research and development activity during the year.

Quarter 4 - FY26 Review

Lumos recorded unaudited revenue of US\$2.3 million for the quarter ended 30 June 2026, down 14% on the pcp.

The Products business generated revenue of US\$0.2 million, representing a 49% decline compared with the pcp, as the pcp included some last-minute stocking orders from a previous distributor, who have since been replaced with PHASE. FebriDx® sales were lower than in the previous quarter (Q3 FY26), primarily reflecting the expected seasonally lower trading conditions during the current fourth quarter and timing of shipments and recognition of substantial PHASE sales orders during the third quarter, in February and March 2026.

Sales from the third-party supplied CorDx Flu A/B/COVID combo test were unable to achieve the sales delivered by ViraDx® in the pcp.

The Services business generated revenue of US\$2.1 million, a decrease of 10% on the pcp. During the quarter, work continued on 12 customer projects, driving 39% growth in contract research and development services revenue. However, total revenue for Services was affected by the lower amortization rate on the Hologic IP licence fee (US\$0.1 million recognized in Q4 FY26 v's US\$0.9 million in Q4 FY25), following the extension of fFN project timeline.

Products Division

We provide a summary of the following product updates below:

FebriDx®

FebriDx® is Lumos' unique, rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a simple fingerstick blood sample after 10 minutes. To date, Lumos has received regulatory registrations for the use of FebriDx® in the U.S., UK, Europe, Kuwait, UAE and Australia.

Moreover, the U.S. FDA's granting of a CLIA waiver for FebriDx on 27 March 2026 marked a transformative milestone for the Company. The CLIA waiver expands the addressable market for FebriDx® by approximately 15-fold, extending its availability to over 300,000 locations across the U.S.¹. This significantly broadens access to over 80 million U.S. patients presenting with acute respiratory infections per annum and unlocks a total market opportunity exceeding US\$1.0 billion. The waiver enables product adoption across a wide range of healthcare settings holding a Certificate of Waiver, including primary care physician offices, urgent care clinics, retail health & pharmacy clinics and community health centres.

Lumos has an exclusive distribution agreement for the U.S. market for FebriDx® with PHASE valued at US\$317 million over 6 years (ASX: 16 July 2025). Under this agreement, the granting of CLIA waiver triggered an immediate payment of US\$5.0 million from PHASE, which was received on 14 April 2026. Additionally, on 7 May 2026 Lumos received a US\$0.5 million milestone payment under its contract with BARDA for achieving CLIA waiver.

WellStreet Urgent Care

On 14 April 2026, Lumos received confirmation that WellStreet Urgent Care will expand its FebriDx® program from the single initial pilot site in Atlanta to a further 43 locations across the Fayetteville District; a second Georgia district; and the entire Michigan market. This initial expansion was completed by mid-June 2026. The third and final expansion phase will see the rollout to all 165 WellStreet sites over the next 3-9 months, with the aim to have as many sites as possible active by the forthcoming U.S. flu season.

U.S. Commercialisation Update

This expanded market opportunity is closely aligned with Lumos' U.S. commercialisation strategy, which is focused on accelerating adoption through targeted healthcare provider education, integration of FebriDx® into outpatient clinical workflows, and the expansion of reimbursement coverage from private payors.

¹ Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid services, March 2024 (CMS CLIA Database).

These initiatives are being supported through the Company's strategic partnerships with PHASE, PRO-spectus, AcuityMD and, most recently, MTMC, which has been engaged to provide clinical implementation training and support to Tier 1 and Tier 2 customers. In addition, Lumos partnered with CG Life as its strategic marketing partner to accelerate FebriDx® commercialisation in the U.S. and drive stronger market awareness across the outpatient segment. This partnership followed a competitive agency review and is a key step in building the commercial engine to support FebriDx® sales growth. Engaging CG Life is an important step in building the commercial infrastructure required to fully realise the FebriDx® opportunity in the U.S. outpatient market. Their diagnostics expertise and commercialisation experience will help us drive awareness, generate demand, and support broader adoption of FebriDx®.

Lumos' initial commercial focus is on Tier 1 and Tier 2 customers, comprising the top 100 Urgent Care operators in the U.S., representing approximately 40% of U.S. urgent care clinics, and totaling more than 5,700 clinical sites nationwide.

As of the date of this announcement, more than 170+ healthcare locations (including WellStreet's 44 sites) across 24 states were actively ordering and using FebriDx®. Importantly, early indications are that reimbursement outcomes have exceeded expectations, with more than 90% of submitted claims successfully reimbursed. With a Medicare benchmark reimbursement rate of US\$41.38 per test and private payor reimbursement generally exceeding this level, Lumos believes a sustainable and attractive economic model can be established for providers, distributors and the Company.

CLIA waived paediatric study continues: On 1 September 2025, BARDA exercised its option to support Lumos in conducting a clinical study and regulatory submission aimed at expanding the age eligibility for FebriDx® use to include children 2 to 12 years of age in CLIA waived settings ("paediatric study"). The study commenced in late October 2025, is being conducted across multiple clinical sites in the US and is expected to run for around 12 months. The Company continues to work with BARDA and the FDA on the best approach to study design and regulatory pathway to reach the required endpoint, following which a formal submission will be prepared for the FDA. An update will be provided closer to the end of the calendar year 2026 on progress and if any changes are made to the study.

Milestone payments from BARDA to Lumos of US\$6.2 million will be triggered upon the achievement of twelve milestone events, including clinical trial set-up, patient recruitment, FDA application submission, and FDA granting of 510(k) clearance and CLIA waiver categorization for children 2 – 12 years of age.

During the quarter, Milestone #7 was successfully completed, following the enrolment of 250 patients. Completion of this milestone triggered a US\$670,000 payment under the Company's agreement with BARDA, which has since been received. Including this latest payment, Lumos has now received cumulative milestone payments of US\$2.6 million under the BARDA Paediatric Study agreement, reflecting continued progress in the clinical development program and ongoing support from BARDA for the advancement of FebriDx® in the paediatric setting.

Development Services and Contract Manufacturing Division

Lumos generates revenue from the provision of point-of-care diagnostic test and custom reader development services, contract manufacturing and IP license revenue. Development services included ongoing work on 12 projects during the quarter, including projects for Hologic, Micro-Pak, TeleMedVet and Aptatek Biosciences.

Hologic -fFN Diagnostic Product

On 11 January 2024, Lumos announced an IP licensing agreement (worth US\$10.0 million, with payment received in FY24) and a Development Agreement (initially worth US\$4.7 million) with Hologic, a leading global women's health provider, to develop the next generation of Hologic's on market fFN diagnostic product for pre-term birth, for which Hologic is the only global manufacturer. A key focus of the development program is to adapt the test for use on the Lumos proprietary reader platform and provide improved connectivity options.

Since the last quarterly report (20 April 2026), the development project has since been expanded by a sixth additional scope of work (SOW), relating to hardware works in Phase 3. A breakdown of the expanded SOW's reported in FY26 is as follows:

1. March 2025 for between US\$0.6 - US\$0.8 million (relating to the delivery of the system prototype in Phase 3)
2. August 2025 for between US\$0.7 - US\$0.9 million (relating to the assay feasibility work in Phase 2)
3. November 2025 for between US\$0.5 - US\$0.6 million (relating to assay feasibility work in Phase 2)
4. February 2026 for US\$0.2 million (relating to hardware works in Phase 3);
5. March 2026 for US\$0.3 million (relating to software works in Phase 3); and
6. May 2026 for US\$0.1 million (relating to hardware works in Phase 3).

Including the six additional SOW's, the body of work under the Development Agreement is being conducted across three phases (which include the nine original milestones), providing total milestone payments of between US\$7.0 - US\$7.7 million, structured as follows:

- Phase 1 (milestone 1) - Product Definition and Planning: define the parameters for the product and establish a project plan - US\$0.4 million – this phase has been completed, and payment has been received;
- Phase 2 (milestones 2 and 3) - Assay Feasibility: conduct work to demonstrate the assay can detect the biomarkers - US\$3.0 to US\$3.3 million – work on the first milestone of this phase has been completed. Work on the second and final milestone for this phase, including the two additional SOW's is expected to be completed by the end of August 2026. For this phase, payments of US\$2.8 million have been received to-date.
- Phase 3 (milestones 4 to 9) - System Prototype Delivery: deliver a working prototype of the system – US\$3.6 - US\$4.0 million – milestone 4 and 5 of this phase are in progress, including the four additional SOW's. Whilst Lumos completes the additional SOW's on assay feasibility and the hardware, work on these initial phase 3 milestones is likely to be delayed, so the estimated timeline

for the project has been pushed out to around June 2028. For this phase, payments of US\$1.2 million have been received to-date.

Summary of Cash Receipts and Outflows

Cash Flow Summary:

US\$000	Quarter 4 (FY26 – 3 months)	Full Year (FY26 - 12 months)
Opening cash	1,132	1,956
Operating cash flow:		
Receipts from customers	6,979	17,842
Payments to suppliers and employees	(5,842)	(21,770)
Net finance costs	(138)	(549)
Government grants and tax incentives	1,680	5,152
Net cash from / (used in) operating activities	2,679	675
Net cash from / (used in) investing activities	(2,253)	(2,485)
Net cash from / (used in) financing activities	13,753	15,118
Net increase / (decrease) in cash	14,179	13,308
Effect of movement in exchange rates on cash held	118	165
Closing cash	15,429	15,429

Lumos generated cash receipts from customers of US\$7.0 million for the quarter ended 30 June 2026, compared to US\$1.8 million receipts from customers in the pc. Included in the receipts from customers is the US\$5.0 million pre-payment from PHASE upon the granting of CLIA waiver for FebriDx®.

Payments to suppliers and employees for Q4 FY26 were US\$5.8 million, an increase of US\$2.3 million over Q4 FY25 payments of \$3.5 million. This was primarily due to growth in the business, increasing investment in inventory and the costs associated with conducting the paediatric study.

During the quarter cash receipts of US\$1.7 million from government grants and tax incentives, comprising US\$1.2 million in payments from BARDA for the paediatric study and US\$0.5 million from the Australian R&D tax incentive.

In total, the net operating cash inflow for Q4 FY26 was US\$2.7 million, an improvement of US\$4.4 million from the outflow of US\$1.7 million reported in the pc.

As advised at the time of the capital raise, Lumos is undertaking building works to expand manufacturing capacity at its Carlsbad facility. During Q4 FY26, the Company made payments to the general contractor of US\$2.1 million in connection with the expansion. These payments (treated as Construction in Progress) have been recorded as capital expenditure for property, plant and equipment. The work is expected to be completed in November 2026, with an estimated \$0.5 million remaining to be spent in 1H FY27.

During the period, the Company received US\$13.3 million (net of costs) from the institutional placement and Share Purchase Plan. A further US\$1.5 million was received from the exercise of unlisted options.

During the quarter, a payment of US\$0.7 million (A\$ 1.0 million) was made relating to the loan facility from Tenmile and Ryder Capital to repay this loan in full. The loan facility was closed and security released on 2 July 2026.

After including investing and financing activities, net cash inflow for the quarter totaled US\$14.2 million, bringing the cash balance at the end of Q4 FY26, to US\$15.4 million.

Post Reporting Date

On 2 July 2026, the Company fully repaid and closed the A\$5.0 million secured Loan Facility with major shareholders Tenmile and Ryder Capital. The Loan Facility, established on 9 September 2025, was designed to provide working capital flexibility as Lumos progressed toward obtaining CLIA waiver approval from the U.S. FDA for its flagship diagnostic test, FebriDx®.

As at the date of this announcement the Company has no debt, and the security interests held by the lenders pursuant to the Loan Facility have now been released.

On 21 July 2026, the Company provided an update on FebriDx® Commercial Traction Advancing Across Priority U.S. Accounts. Announcing that a leading regional top 100 U.S. urgent care group, owned and operated by a major U.S. health system, has agreed to deploy FebriDx® across its entire urgent care network of more than 30 sites, representing an opportunity of ~200,000 acute respiratory infection (ARI) presentations per year². Within the broader U.S. market, approximately 58 of the top 100 urgent care groups are owned by or affiliated with large health systems³, highlighting the strategic importance of this channel for Lumos. This specific health system operates more than 200 sites across a major U.S. metropolitan region, including urgent care centres, hospitals, ambulatory clinics and medical group practices. FebriDx® is expected to support ARI triage protocols, antibiotic stewardship initiatives and standardised workflows across urgent care and related ambulatory settings, with the potential to advance toward standardised adoption across this health system's broader network.

In addition, three urgent care groups, including a top 10, a top 25 and a top 30 organisation, are currently progressing through clinical and economic validation across multiple sites. In total, these accounts represent more than 230 urgent care sites and offer a meaningful opportunity for future network deployment.

Recently the Company has just secured a commitment from an additional top 100 urgent care organisation that is owned and operated by one of the southeast's largest not-for-profit, integrated healthcare systems. A network of more than 400 care locations, supported by over 35,000 team members and one of the

² Average ARI visits per US urgent care site: ~4,000–5,500 per year. Urgent Care Association Data (2025); Health Care Cost Institute, "Respiratory-Related Illness is the Top Reason People Use Urgent Care" (analysis of 73M commercial urgent care visits, 2018–2022).

³ Journal of Urgent Care Medicine 2025

region's largest physician networks. The health system operates more than 25 urgent care sites, creating a meaningful future deployment opportunity if validation outcomes are successful.

Payments to Related Entities

In accordance with Listing Rule 4.7C.3 and as outlined in Section 6.1 of Appendix 4C, the Company discloses payments of US\$293,000, comprising directors' fees and superannuation for Sam Lanyon, Catherine Robson, Bronwyn Le Grice, directors' fees for Larry Mehren (paid to his related entity, RBLM Consulting), consulting fees for Sam Lanyon, and salary, bonus, medical insurance and 401K retirement payments for Doug Ward. Mr Ward does not receive any additional fees for being a director.

The consulting fees for Sam Lanyon are for advisory services in relation to investor relations, capital raising and commercialisation activities (ASX: 28 September 2023). Mr Lanyon receives A\$80,000 per annum, inclusive of superannuation, for these services.

The Company also notes the share purchases made by Mr Lanyon and Ms Catherine Robson as included in the Appendix 3Y Notices announced on 24 June 2026 and 18 June 2026 respectively.

Key Priorities

The key focus areas for Lumos are currently summarised as follows:

In the year ahead, Lumos will prioritise continued growth in the U.S. market by driving sales of FebriDx® through the implementation of its agreement with PHASE. Key initiatives will include increasing market awareness, expanding clinical adoption, progressing reimbursement coverage, and supporting manufacturing scale-up to meet growing demand. These efforts are aimed at strengthening FebriDx®'s position as a valuable point-of-care diagnostic tool within the U.S. healthcare system.

The Company will also advance its BARDA-supported paediatric study for FebriDx®, targeting the 2–12 age group, to address an important unmet clinical need and expand the U.S. addressable market for FebriDx® by an estimated 15% to 20%. In parallel, Lumos will continue delivering on its development programs with Hologic and other key customers.

In closing, CEO Doug Ward said: *"We are encouraged by the progress achieved since securing CLIA waiver for FebriDx®, with commercial adoption tracking ahead of our expectations. These early results reinforce the value proposition of FebriDx® for providers, payers and patients, and validate the significant commercial opportunity ahead of us."*

"As we prepare for the upcoming U.S. respiratory season, our focus is on increasing market awareness, expanding site adoption, driving utilisation within existing accounts, and supporting reimbursement activities and our distributor partner, PHASE, as they continue to scale market penetration."

Webinar Invitation

The Company invites investors and analysts to attend its Q4 FY26 results webinar, to be held online on Wednesday, 29 July 2026 at 10.15am (AEST.)

Participants can register ahead of time, via the following link:

https://us02web.zoom.us/webinar/register/WN_nYvzMUPJQleS29qe_nqeCQ

Once the registration form is complete, investors will receive a confirmation email with details on how to access the meeting. The Lumos team looks forward to welcoming all those who are able to attend.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact: Haley Chartres – Australia H^CK Director haley@hck.digital +61 423 139 163	Investor Contact: George Kopsiaftis IR Specialist, IR Department ir@lumosdiagnostics.com +61 409 392 687	Company Registered Office: Lumos Diagnostics Holdings Ltd Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 info@lumosdiagnostics.com +61 3 9087 1598
---	--	--

Appendix 4C

Quarterly Cash Flow report for entities subject to Listing Rule 4.7B

Name of entity

Lumos Diagnostics Holding Limited

ABN

66 630 476 970

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter US\$'000	Year to date (12 months) US\$'000
1. Cash flows from operating activities		
1.1 Receipts from customers	6,979	17,842
1.2 Payments for		
(a) service delivery, research and development	(1,097)	(4,272)
(b) product manufacturing and operating costs	(1,445)	(4,629)
(c) sales, advertising and marketing	(510)	(1,637)
(d) medical affairs and clinical trial costs	(540)	(2,709)
(e) leased assets	-	-
(f) staff costs*	(1,319)	(5,568)
(g) administration and corporate costs	(931)	(2,955)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	41	52
1.5 Interest and other costs of finance paid	(179)	(601)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	1,680	5,152
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	2,679	675

*Staff costs have been allocated to their respective departments above.

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(2,253)	(2,485)
(d) investments	-	-

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (12 months) US\$'000
	(e) intellectual property	-	-
	(f) other non-current assets (including capitalised product development costs)	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(2,253)	(2,485)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	14,305	14,305
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	1,536	3,002
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(1,040)	(1,040)
3.5	Proceeds from borrowings	-	686
3.6	Repayment of borrowings	(776)	(776)
3.7	Transaction costs related to loans and borrowings	-	(13)
3.8	Dividends paid	-	-
3.9	Other:		
	Lease payments (principal component)	(272)	(1,046)
3.10	Net cash from / (used in) financing activities	13,753	15,118

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (12 months) US\$'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,132	1,956
4.2	Net cash from / (used in) operating activities (item 1.9 above)	2,679	675
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2,253)	(2,485)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	13,753	15,118
4.5	Effect of movement in exchange rates on cash held	118	165
4.6	Cash and cash equivalents at end of period	15,429	15,429

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter US\$'000	Previous quarter US\$'000
5.1	Bank balances	15,429	1,132
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	15,429	1,132

6.	Payments to related parties of the entity and their associates	Current quarter US\$'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	293
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end US\$'000	Amount drawn at quarter end US\$'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	US\$'000
8.1	Net cash from / (used in) operating activities (item 1.9)	2,679
8.2	Cash and cash equivalents at quarter end (item 4.6)	15,429
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	15,429
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A		
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A		

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **27 July 2026**

Authorised by: **The Lumos Disclosure Committee**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.